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Abstract

Research Questions

▪ In 1996, the state of California was the first in the union to allow for
the use of medical marijuana. Since then, 28 more states have enacted
similar laws (National Conference of State Legislatures, [NCSL],
2017).
▪ As of 2014, the CDC reported opioid deaths were up 369%, which is
more than 91 deaths per day from overdose (Centers for Disease
Control, [CDC], 2017). The purpose of this study is to compare
medical marijuana to opiates in safety and addiction; in addition, the
efficacy of using cannabis as an alternative for individuals who deal
with chronic pain will be investigated.
▪ A literature review was conducted to find systematic reviews, metaanalyses and randomized controlled trials (RCTs) that evaluated
medical marijuana and opiates for the treatment of chronic pain.
▪ Four databases were surveyed with multiple sources found in
CINAHL, Cochrane Database, PubMed and PsycINFO.
▪ Current literature shows that cannabinoids may provide potential
benefit with short-term use, but not without possible adverse effects.
With the current lack of research on long-term treatment of chronic
pain with cannabinoids, additional research needs to be conducted to
further understand the potential adverse effects associated with
cannabinoid use.
▪ Keywords: adverse effects, cannabinoid addiction, cannabinoids,
chronic pain, efficacy, medical marijuana, pain management.

▪ Is medical cannabis safe to use for chronic pain? What are the
documented adverse effects associated with using this medication?
▪ How addictive is medical cannabis compared to other addictive
substances? What addictive qualities are associated with starting this
medication?
▪ What has been shown to be more effective in the treatment of chronic
pain, medical cannabis or opiates?

Introduction
▪ Cannabis, cannabinoids and medical marijuana all encompass a topic
that is highly controversial, as well as lacking in scientifically based
evidence for chronic pain therapy. To date, the Food and Drug
Administration (FDA) has approved three different cannabinoid based
products that are currently being used for various medical issues, such
as Dronabinol (Marinol and Syndros) and Nabilone (Cesamet).
▪ Limited amounts of research have been conducted due to the Drug
Enforcement Administrations (DEA) schedule of cannabis as a
Schedule I drug.
▪ Chronic pain is also a highly discussed topic due to the difficult nature
of finding proper therapy to improve overall quality of life. Patients
who deal with chronic pain are often left with prescription opiates for
pain management, all of which have adverse effects. Authors
Feingold, Goor-Aryeh, Bril, Delayahu, and Lev-Ran (2017) state
long-term treatment with opioids may be complicated due to tolerance
and addiction, which may not be adequately managed and potentially
worsen the pain.
▪ An in-depth evaluation of the adverse reactions, addictive effects, as
well as clinical and statistical significance will be examined in those
who choose to try cannabinoid products for chronic pain therapy.

Literature Review
▪ Cannabinoids for Chronic Pain- Safety and Adverse Events
▪ Whiting et al. (2015) found in eight of the 28 studies, patients
who reported at least 30% decrease in pain were those who used
cannabinoids rather than those who used a placebo (OR = 1.41;
95% CI =0.99-2.00). They also found common adverse events
that included dizziness, dry mouth, nausea, fatigue,
hallucinations, drowsiness and confusion.
▪ Results found by Ware, Wang, Shapiro, and Collet (2015),
showed medical cannabis users were at increased risk of nonserious adverse events, 818, ranging from mild to moderate
events such as: headache, nasopharyngitis, nausea, somnolence,
and dizziness compared to the 581 events documented in the
control (IRR = 1.64, 95% CI = 1.35-1.99). Overall, individuals in
the medical cannabis group experienced better pain control than
the control (change = .92; 95% CI = .62-1.23) vs (change = .18;
95% CI = -.13).
▪ Nugent et al. (2017) found no detection of significant differences
between the cannabis group compared to the control group when
it came to serious adverse events (IRR = 1.08; 95% CI = 0.572.04). This study did evaluate long-term effects associated with
cannabis use and found it to be associated with cannabinoid
hyperemesis syndrome as well as incident cannabis use disorder
(OR = 9.5; 95% CI = 6.4-14.1)
▪ Comparison of Addictive Substances to Cannabinoids
▪ Feingold, Goor-Aryeh, Bril, Delayahu, and Lev-Ran (2017)
studied whether or not these patients were more apt to abuse
opioids or medical cannabis. Figure I shows the results.
▪ Richter, Pugh, Smith, and Ball (2016) examined alcohol,
marijuana, as well as other illicit drugs and prescription drugs as
possible correlates to nicotine product use. Results revealed any
form of nicotine use, co-occurring use with other substances was
documented (79.4% alcohol (OR = 11.5; 95% CI = 8.4- 15.7),
59.7% marijuana (OR = 12.7%; 95% CI = 9.5- 16.8), 53.9%
poly-substance use (OR = 15.5; 95% CI = 11.4- 21.0), 18.8%
prescription drugs (OR = 8.3; 95% CI = 5.4- 12.8), 8.5% other
illicit drugs (OR = 19.1; 95% CI = 9.0- 40.6).

Literature Review Cont.
▪ Medical Cannabis vs Opiate Efficacy
▪ Goldenberg, Reid, IsHak, and Danovitch (2017) found cannabis
use for increased health-related quality of life (HRQoL) had vague
results and most effects were non-significant or nearing zero. Some
reports showed a mild benefit in some pain conditions while in
others there was a decrease in HRQoL.
▪ Narang, Gibson, Wasan, Ross, Michna, Nedeljkovic, and Jamison
(2008) conducted two phases and found Dronabinol in Phase I had
significant pain relief after 8 hours per the total pain relief at 8
hours score (TOTPAR), (20 mg vs placebo at p < .01, 10 mg vs
placebo at p < .05). For adjuvant therapy in Phase II, dronabinol
proved to have a significant effect in lowering pain from baseline
(p < .001), decreasing pain bothersomeness, as well as increased
satisfaction in their therapy (p < .01).
▪ Boehnke, Litinas, and Clauw (2016) evaluated the efficacy of
medical cannabis compared to opiates in chronic pain patients.
Figure II highlights the changes before and after cannabis use.

Discussion

K. Boehnke, E. Litinas, D. Clauw, 2016

▪ The National Institutes of Health (NIH) has supported around 281
projects totaling over $111 million on cannabinoid research, 49
projects ($21 million) examined therapeutic properties of
cannabinoids, and 15 projects ($9 million) focused on (CBD)
▪ Medical cannabis has multiple adverse events similar to other drugs
▪ Medical cannabis has been found to be less addictive and problematic
than opiates according to the literature review, reference the pie chart
▪ Medical cannabis has been shown to improve overall HRQoL and
reduce medication need, not always statistically but clinically
▪ More research is needed to understand the long term effects as well as
short term outcomes in larger populations

Statement of the Problem
▪ According to Boehnke, Litinas, and Clauw (2016), opiates are one of
the most commonly used medications to treat chronic pain. With that
notion, opiates are also ineffective for many types of pain as well as
associated with addictive and significant morbidity and mortality
rates.
▪ With the ever-growing opiate epidemic, an alternative treatment
modality would be of great benefit. Cannabinoid therapy could be a
potential secondary option rather than continued opiate therapy if
research supports the advocacy and safety.

Applicability to Clinical
Practice
▪ It is difficult to find effective treatments for chronic pain, but having
multiple therapy modalities increases the likelihood of controlling pain
▪ Alternative therapies will aid in alleviating the current opiate epidemic
▪ Medical cannabis has also been shown to be effective for other
diseases such as fibromyalgia, neuropathy, multiple sclerosis, cystic
fibrosis, migraines and gastrointestinal conditions
▪ Medical cannabis is associated with reduced risk of addiction, lessened
side effects and a possible decrease in other pain medications
compared to opiates

References
▪ Boehnke, K., Litinas, E., & Clauw, D. (2016). Medical cannabis use is associated with
decreased opiate medication use in a retrospective cross-sectional survey of patients with
chronic pain. The Journal of Pain, 17(6), 739-744.
http://doi.org/10.1016/j.jpain.2016.03.002
▪ Centers for Disease Control and Prevention (2017). Opioid overdose; understanding the
epidemic. Retrieved from https://www.cdc.gov
▪ Feingold, D., Goor-Aryeh, I., Bril, S., Delayahu, Y., & Lev-Ran, S. (2017). Problematic
use of prescription opioids and medical cannabis among patients suffering from chronic
pain. American Academy of Pain Medicine, 18(2), 294-306.
http://doi.org/10.1093/pm/pnw134
▪ Goldenberg, M., Reid, M., IsHak, W., & Danovitch, I., (2017). The impact of cannabis
and cannabinoids for medical conditions on health-related quality of life: A systematic
review and meta-analysis. Drug and Alcohol Dependence, 174, 80-90.
http://doi.org/10.1016/j.drugalcdep.2016.12.030
▪ Lüscher, C. (2018). Drugs of abuse. In B.G. Katzung (Ed.), Basic & clinical
pharmacology, 14e (Chapter 32). New York, NY: McGraw-Hill. Available from
AccessMedicine
▪ National Conference of State Legislatures (2017). State medical marijuana laws.
Retrieved from https://www.ncsl.org
• National Institutes of Health (2017). Commonly abused drugs. National institute on drug
abuse. Retrieved from http://www.drugabuse.org
▪ Narang, S., Gibson, D., Wasan, A., Ross, E., Michna, E., Nedeljkovic, S., & Jamison R.
(2008). Efficacy of Dronabinol as an adjuvant treatment for chronic pain patients on
opioid therapy. The Journal of Pain, 9(3), 254-264.
http://doi.org/10.1016/j.jpain.2007.10.018
▪ Nugent, S., Morasco, B., O’Neil, M., Freeman, M., Low, A., Kondo, K., . . . Kansagara,
D. (2017). The effects of cannabis among adults with chronic pain and an overview of
general harms. Annals of Internal Medicine, 167(5), 319-332.
http://doi.org/10.7326/M17-0155
▪ Richter, L., Pugh, B., Smith, P., & Ball, S. (2016). The co-occurrence of nicotine and
other substance use and addiction among youth and adults in the United States:
Implication for research, practice, and policy. The American Journal of Drug and
Alcohol Abuse, 43(2), 132-145. http://doi.org/10.1080/00952990.2016.1193511
▪ Ware, M., Wang, T., Shapiro, S., & Collet, J. (2015). Cannabis for the management of
pain: Assessment of safety study. The Journal of Pain, 16(12), 1233-1242.
http://doi.org/10.1016./j.jpain.2015.07.014
▪ Whiting, P., Wolff, R., Deshpande, S., Di Niso, M., Duffy, S., Hernandez, A., . . .
Kleijnen, J., (2015). Cannabinoids for medical use: A systematic review and metaanalysis. JAMA, 313(24) 2456-2473. https://doi.org/10.1001/jama.2015.6358

Acknowledgements
To my husband Nick and son Ellis, thank you for supporting and
encouraging me so I could achieve my dream.
▪ I wish to express my most sincere appreciation to Julie Solberg, PA-C
and Daryl Sieg, PA-C for their support through this program.
▪ A special thank you to Dawn Hackman, MS, AHIP, Marilyn G. Klug,
PhD, and Andres Makarem, MD for their assistance and expertise.
D. Feingold, I. Goor-Aryeh, S. Bril, Y. Delayahu, and S. Lev-Ran, 2017

B.G. Katzung (Ed.), 2014

